Cognitive disorders in patients with cerebrovascular diseases in therapeutic practice: diagnostic and management algorithms

This review summaries  the main present-day knowledge  on the pathogenesis of cognitive impairement in patients with cardiovascular and cerebrovascular diseases,  combining  both the development of severe  forms such as dementia, and early non-dementia forms of cognitive  impairment.  Risk factors, including  iatrogenic  ones, and the  mechanisms of development of various forms of cognitive impairment in patients with vascular pathologies are discussed  in detail. The definition of human cognitive functions and the modern classification  of cognitive impairment used in real clinical practice are given.  The clinical aspects  of cognitive impairment  in the  therapeutic practice  with a focus on the  review of a wide range  of specific complaints,  reflecting  the  likelihood  of cognitive impairment and non-cognitive symptoms are considered in detail, taking into account the current national  clinical guidelines of professional communities. Possible iatrogenic  factors that worsen the state  of cognitive functions, including an assessment of the anticholinergic drug load on the patient  are discussed  in detail, and a strategy for identifying and solving this issue as part of a therapeutic approach is provided. An algorithmic approach to the identification of non-dementia cognitive impairment in patients with cerebrovascular pathology  is presented by therapeutic specialists  working in the  primary outpatient healthcare sector. The laboratory and instrumental examination options for patients to identify reversible forms of cognitive impairment are considered in detail. The prospective of choosing preventive  non-drug and drug approaches, as well as the therapeutic strategy options for the use  of drugs  that  improve  the  central  nervous  system  functioning  during  management of patients with  cerebrovascular diseases, depending on the type of cognitive impairment in the general  practitioner practice are assessed.

1. Tkacheva O.N., Yakhno N.N., Neznanov N.G., Levin O.S., Gusev E.I., Martynov M. Yu. et al. Cognitive disorders in the elderly and senile. Clinical recommendations. Moscow; 2020. (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/617_1.

2. Levin O.S. Diagnosis and treatment of cognitive impairment and dementia in clinical practice. Moscow: MEDpress-inform; 2019. 448 p. (In Russ.)

3. Yakhno N.N., Zakharov V.V. Cognitive and emotional-affective disorders in dyscirculatory encephalopathy. RMJ. 2002;(12–13):539–542. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Kognitivnye_i_emocionalyno-affektivnye_narusheniya_pri_discirkulyatornoy_encefalopatii/?ysclid=l9b4zshdbs442005354.

4. Dichgans M., Leys D. Vascular Cognitive Impairment. Circ Res. 2017;120(3):573–591. https://doi.org/10.1161/CIRCRESAHA.116.308426.

5. Kostyuk G.P. (ed.). Mental and behavioral disorders and disorders of neuropsychic development. Moscow; 2021. 432 р. (In Russ.) Available at: https://psymos.ru/storage/oaxiMThNYRwgeVDUGujm/ScpzAmSbEeIwrJKifpHdbmSRmLtT6AuVXHIoFXI6.pdf.

6. Jeste D.P., Lieberman F.A., Fassler T.D., Peele R., Benson R.S., Young M.L. et al. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Publishing; 2013. 970 р. Available at: https://cdn.website-editor.net/30f11123991548a0af708722d458e476/files/uploaded/DSM%2520V.pdf.

7. Tkacheva O.N., Nedogoda S.V., Arutyunov G.P., Boitsov S.A., Vertkin A.L., Villevalde S.V. et al. Pharmacotherapy in the elderly and senile. Moscow; 2018. 87 р. (In Russ.) Available at: https://rgnkc.ru/images/metod_materials/Farmakoterapiya_2018.pdf.

8. Tkacheva O.N., Nedogoda S.V., Arutyunov G.P., Boitsov S.A., Vertkin A.L., Villevalde S.V. et al. Senile asthenia: clinical recommendations. Moscow; 2018. 150 р. (In Russ.) Available at: https://rgnkc.ru/images/pdf_documets/Asteniya_final_2018.pdf.

9. Ghafar M.Z.A.A., Miptah H.N., O’Caoimh R. Cognitive screening instruments to identify vascular cognitive impairment: A systematic review. Int J Geriatr Psychiatry. 2019;34(8):1114–1127. https://doi.org/10.1002/gps.5136.

10. Chen T.B., Yiao S.Y., Sun Y., Lee H.J., Yang S.C., Chiu M.J. et al. Comorbidity and dementia: A nationwide survey in Taiwan. PLоS ONE. 2017;12(4):e0175475. https://doi.org/10.1371/journal.pone.0175475.

11. Schneider A.L., Jonassaint C., Sharrett A.R., Mosley T.H., Astor B.C., Selvin E. et al. Hemoglobin, Anemia, and Cognitive Function: The Atherosclerosis Risk in Communities Study. J Gerontol A Biol Sci Med Sci. 2016;71(6):772–779. https://doi.org/10.1093/gerona/glv158.

12. Berger I., Wu S., Masson P., Kelly P.J., Duthie F.A., Whiteleyet W. et al. Cognition in chronic kidney disease: a systematic review and meta-analysis. BMC Med. 2016;14(1):206. https://doi.org/10.1186/s12916-016-0745-9.

13. Hadjihambi A., Arias N., Sheikh M., Jalan R. Hepatic encephalopathy: a critical current review. Hepatol Int. 2018;12(Suppl. 1):135–147. https://doi.org/10.1007/s12072-017-9812-3.

14. Rieben C., Segna D., da Costa B.R., Collet T.H., Chaker L., Aubertet C.A. et al. Subclinical Thyroid Dysfunction and the Risk of Cognitive Decline: a Meta-Analysis of Prospective Cohort Studies. J Clin Endocrinol Metab. 2016;101(12):4945–4954. https://doi.org/10.1210/jc.2016-2129.

15. Najafi L., Malek M., Hadian A., Valojerdi A.E., Khamseh M.E., Aghili R. Depressive symptoms in patients with subclinical hypothyroidism – the effect of treatment with levothyroxine: a double-blind randomized clinical trial. Endocr Res. 2015;40(3):121–126. https://doi.org/10.3109/07435800.2014.896924.

16. Ford A.H., Almeida O.P. Effect of Vitamin B Supplementation on Cognitive Function in the Elderly: A Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(5):419–434. https://doi.org/10.1007/s40266-019-00649-w.

17. Smith A.D., Refsum H., Bottiglieri T., Fenech M., Hooshmand B., McCaddon A. et al. Homocysteine and Dementia: An International Consensus Statement. J Alzheimers Dis. 2018;62(2):561–570. https://doi.org/10.3233/JAD-171042.

18. De Francesco D., Winston A., Underwood J., Cresswell F.V., Anderson J., Post F.A. et al. Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals. Int J STD AIDS. 2019;30(5):440–446. https://doi.org/10.1177/0956462418817612.

19. Arangalage D., Ederhy S., Dufour L., Joffre J., Van der Vynckt J., Lang S. et al. Relationship between cognitive impairment and echocardiographic parameters: a review. J Am Soc Echocardiogr. 2015;28(3):264–274. https://doi.org/10.1016/j.echo.2014.11.009.

20. Islam M.M., Poly T.N., Walther B.A., Yang H.C., Wu C.C., Lin M.C. et al. Association Between Atrial Fibrillation and Dementia: A Meta-Analysis. Front Aging Neurosci. 2019;11(305):1–15. https://doi.org/10.3389/fnagi.2019.00305.

21. Li X., Ma X., Lin J., He X., Tian F., Kong D. Severe carotid artery stenosis evaluated by ultrasound is associated with post stroke vascular cognitive impairment. Brain Behav. 2017;7(1):e00606. https://doi.org/10.1002/brb3.606.

22. Song D., Yu D.S.F., Li P.W.C., Lei Y. The effectiveness of physical exercise on cognitive and psychological outcomes in individuals with mild cognitive impairment: A systematic review and meta-analysis. Int J Nurs Stud. 2018;79:155–164. https://doi.org/10.1016/j.ijnurstu.2018.01.002.

23. Shishkova V.N. Place of arterial hypertension in brain lesion development – from minor cognitive disorders to dementia. Systemic Hypertension. 2014;(1):45–51. (In Russ.) Available at: https://journals.eco-vector.com/files/journals/79/articles/29008/public/29008-57865-1-PB.pdf.

24. Shishkova V.N., Adasheva T.V. The relevance of screening for cognitive and psychoemotional disorders in patients with metabolic syndrome and insulin resistance: A review. Consilium Medicum. 2022;(4):252–255. (In Russ.) https://doi.org/10.26442/20751753.2022.4.201681.

25. Yakhno N.N., Tkacheva O.N., Gavrilova S.I., Levin O.S., Bogolepova A.N., Mkhitaryan E.A. et al. Comprehensive interdisciplinary and interdepartmental program for the prevention, early detection, diagnosis and treatment of cognitive disorders in elderly and senile persons until 2025. Moscow; 2018. 62 p. (In Russ.) Available at: https://rgnkc.ru/images/pdf_documets/Antidement_plan_060919.pdf?ysclid=l9bd7snqf069499437.

26. Ubhi K., Rockenstein E., Vazquez-Roque R., Mante M., Inglis C., Patrick C. et al. Cerebrolysin modulates nerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease. J Neurosci Res. 2013;91(2):167–177. https://doi.org/10.1002/jnr.23142.

27. Shishkova V.N., Adasheva T.V., Remennik A.Yu., Valyaeva V.N., Shklovsky V.M. Prognostic significance of clinical-anthropometric, biochemical, metabolic, vascular-inflammatory and molecular-genetic markers in the development of the first ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;(2):4–11. (In Russ.) https://doi.org/10.17116/jnevro2018118214-11.

28. Shishkova V.N., Adasheva T.V., Stakhovskaya L.V. The role of diabetes mellitus and gender factor in the development of recurrent ischemic stroke of non-cardioembolic genesis. Vrach. 2020;(10):50–54. (In Russ.) Available at: https://vrachjournal.ru/ru/25877305-2020-10-09.

29. Masliah E., Diez-Tejedor E. The pharmacology of neurotrophic treatmentwith Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc). 2012;(Suppl. 48):3–24. https://doi.org/10.1358/dot.2012.48(Suppl.A).1739716.

30. Guekht A.B., Moessler H., Novak P.H., Gusev E.I. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011;20(4):310–318. https://doi.org/10.1016/j.jstrokecerebrovasdis.2010.01.012.

31. Gordeeva I.E., Ansarov Kh.Sh., Sokolova V.Yu. The role of neurotrophic therapy in the treatment of cognitive disorders caused by diabetes mellitus. Consilium Medicum. 2020;(2):35–40. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/95199/pdf.